FY2025 EPS Estimates for Korro Bio Raised by HC Wainwright

Korro Bio, Inc. (NASDAQ:KRRO) – Stock analysts at HC Wainwright increased their FY2025 earnings estimates for Korro Bio in a research note issued to investors on Thursday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($9.24) per share for the year, up from their prior estimate of ($9.93). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2025 earnings at ($2.08) EPS, Q1 2026 earnings at ($1.86) EPS, Q2 2026 earnings at ($1.67) EPS, Q3 2026 earnings at ($1.71) EPS, Q4 2026 earnings at ($1.75) EPS and FY2026 earnings at ($6.99) EPS.

A number of other analysts also recently commented on the company. William Blair downgraded Korro Bio from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 13th. Chardan Capital reaffirmed a “neutral” rating on shares of Korro Bio in a research note on Thursday, November 13th. Raymond James Financial cut shares of Korro Bio from a “strong-buy” rating to a “market perform” rating in a research note on Thursday, November 13th. Royal Bank Of Canada downgraded shares of Korro Bio from an “outperform” rating to a “sector perform” rating in a report on Thursday, November 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Korro Bio in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Korro Bio has an average rating of “Hold” and a consensus target price of $76.00.

Korro Bio Price Performance

KRRO opened at $6.15 on Monday. The stock’s 50 day simple moving average is $37.18 and its 200 day simple moving average is $23.38. The stock has a market cap of $57.93 million, a P/E ratio of -0.65 and a beta of 2.94. Korro Bio has a 1-year low of $5.70 and a 1-year high of $56.69.

Korro Bio (NASDAQ:KRRO) last issued its earnings results on Wednesday, November 12th. The company reported ($1.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.61) by $0.69. The company had revenue of $1.09 million during the quarter, compared to analysts’ expectations of $0.41 million. Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%.

Institutional Investors Weigh In On Korro Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the company. TCG Crossover Management LLC acquired a new position in shares of Korro Bio in the third quarter valued at approximately $19,937,000. Cormorant Asset Management LP purchased a new stake in Korro Bio in the 1st quarter worth approximately $6,621,000. JPMorgan Chase & Co. grew its stake in Korro Bio by 6,185.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock worth $9,542,000 after acquiring an additional 196,079 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Korro Bio in the 3rd quarter valued at $4,319,000. Finally, Driehaus Capital Management LLC lifted its stake in shares of Korro Bio by 17.7% during the 1st quarter. Driehaus Capital Management LLC now owns 582,449 shares of the company’s stock worth $10,140,000 after purchasing an additional 87,544 shares during the period. 13.18% of the stock is currently owned by hedge funds and other institutional investors.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).